Neoadjuvant CAPOXIRI Chemotherapy in the Treatment of Resectable, Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma Protocol
Phase of Trial: Phase II
Latest Information Update: 19 Mar 2019
At a glance
- Drugs Capecitabine (Primary) ; Irinotecan (Primary) ; Oxaliplatin (Primary)
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Therapeutic Use
- 14 Mar 2019 Status changed from active, no longer recruiting to discontinued.
- 21 Feb 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Dec 2018.
- 21 Feb 2018 Status changed from recruiting to active, no longer recruiting.